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Aims Anecdotal observations suggest that sub-clinical electrophysiological manifestations of arrhythmogenic right ventricular
cardiomyopathy (ARVC) develop before detectable structural changes ensue on cardiac imaging. To test this hypothesis,
we investigated a murine model with conditional cardiac genetic deletion of one desmoplakin allele (DSP +) and com-
pared the findings to patients with non-diagnostic features of ARVC who carried mutations in desmoplakin.
Methods
and results
Murine: the DSP (+) mice underwent electrophysiological, echocardiographic, and immunohistochemical studies.
They had normal echocardiograms but delayed conduction and inducible ventricular tachycardia associated with mis-
localization and reduced intercalated disc expression of Cx43. Sodium current density and myocardial histology were
normal at 2 months of age. Human: ten patients with heterozygous mutations in DSP without overt structural heart
disease (DSP+) and 12 controls with supraventricular tachycardia were studied by high-density electrophysiological
mapping of the right ventricle. Using a standard S1–S2 protocol, restitution curves of local conduction and repolar-
ization parameters were constructed. Significantly greater mean increases in delay were identified particularly in the
outflow tract vs. controls (P, 0.01) coupled with more uniform wavefront progression. The odds of a segment with
a maximal activation–repolarization interval restitution slope .1 was 99% higher (95% CI: 13%; 351%, P ¼ 0.017) in
DSP+ vs. controls. Immunostaining revealed Cx43 mislocalization and variable Na channel distribution.
Conclusion Desmoplakin disease causes connexin mislocalization in the mouse and man preceding any overt histological abnor-
malities resulting in significant alterations in conduction–repolarization kinetics prior to morphological changes de-
tectable on conventional cardiac imaging. Haploinsufficiency of desmoplakin is sufficient to cause significant Cx43
mislocalization. Changes in sodium current density and histological abnormalities may contribute to a worsening
phenotype or disease but are not necessary to generate an arrhythmogenic substrate. This has important implications
for the earlier diagnosis of ARVC and risk stratification.
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Introduction
Arrhythmogenic right ventricular (RV) cardiomyopathy (ARVC) is
a primary heart muscle disorder characterized by a high incidence
of ventricular arrhythmias. Early in the disease’s course, before the
manifestation of RV myocyte loss and fibro-fatty replacement,
there is a sub-clinical ‘concealed phase’. This presents a major diag-
nostic and clinical management challenge because arrhythmias and
sudden death may arise in the absence of significant clinical and
pathological changes.1 The recent identification of specific desmo-
somal protein mutations in up to 40% of ARVC patients provides
an opportunity to study the pathophysiology of ARVC, specifically
whether delayed conduction and a pro-arrhythmic substrate occur
in the absence of significant fibrosis.2
Abnormal desmosomal proteins are known to be associated
with reduced gap junctional Connexin 43 (Cx43) expression
which may adversely affect cardiomyocyte electrical coupling.
However, there is considerable conduction reserve in ventricular
myocardium such that a 95% downregulation in Cx43 reduces
transverse conduction velocity (CV) by only 15% and longitudinal
conduction by 58%.3 This has prompted a search for other factors
implicated in maintaining conduction reserve which may exert
deleterious pro-arrhythmic effects. It has been posited that desmo-
somal proteins also directly interact with ion channels at the inter-
calated disc.4,5 Plakophilin-2 (PKP2) and the sodium (Na) channel,
Nav1.5, not only interact but reduced PKP2 expression leads to
reduced Na current peak density and altered channel kinetics as
well as significant reductions in CV in cultured rat neonatal cardi-
omyocytes, suggesting that ion channel function is disrupted in
some forms of ARVC.4 However, this has not been demonstrated
in any other model or in human disease. We hypothesized that if
ARVC begins primarily in the desmosome and alters gap junction
coupling, then the sub-clinical manifestations of disease may be
identified electrophysiologically prior to histological change. We
tested this hypothesis in a murine model with conditional genetic
deletion of one allele of desmoplakin (DSP) in the adult heart
(DSP +) and compared the findings with patients carrying desmo-
plakin mutations.
Methods
Murine
Generation of genetically modified mice
Animals were cared for according to the Animals (Scientific Proce-
dures) Act 1986 (PPL 70/6732). Desmoplakin heterozygotic mice
and littermate controls were generated (see Supplementary Material)
and studied at 2 and 6 months of age to investigate whether electro-
physiological changes occur before overt structural anomalies.6,7
Electrophysiological studies, conduction curves, and
echocardiography
Mice were anaesthetized with 1.5% isoflurane and a lead II ECG was
recorded (Powerlab and Chart software; AD Instruments, Oxford).
A 1.1F octapolar electrophysiology catheter (model EPR-801, Millar
Instruments) was inserted into the right atrium and ventricle via the
jugular vein. The intracardiac electrograms were filtered between 5
and 500 Hz. Pacing stimuli were delivered using the S88 stimulator
(Grass Technologies, USA). Electrophysiology studies, similar to clinic-
al studies, were performed as previously described.8 Pacing output was
set at twice diastolic threshold. Sinus node recovery time (SNRT) was
calculated by atrial pacing at a cycle length of 100 ms for 15 s. Atrio-
ventricular nodal effective refractory period (AVNERP) was calculated
with an atrial drive train at 100 ms and an S2 at 90 ms reduced in 2 ms
decrements until AV block occurred. Right ventricular effective refrac-
tory period (VERP) was calculated using a ventricular drive train at
100 ms and S2 at 70 ms decreased in 2 ms decrements to refractori-
ness. Ventricular tachycardia (VT) stimulation was performed with a
drive train at 100 ms with up to three extrastimuli (S2, S3, S4)
coupled at 70 ms. These were decremented until S2 was refractory.
Ventricular tachycardia was defined as greater than 3 beats of broad
complex tachycardia exhibiting AV dissociation on the intracardiac
electrograms. Mean increase in delay was calculated by dividing the
integrated increase in delay by the interval between the basic cycle
length and the ventricular refractory period.9
Murine histology/immunostaining
Thin sections of myocardial tissue were stained with H&E and Masson
Trichrome to detect fibrosis. For Oil red O staining, sections were
fixed in 4% paraformaldehyde, washed in distilled water, stained with
Oil red O solution in isopropanol, and rinsed in isopropanol. Immu-
nostaining for plakoglobin, Cx43, Na channel, and other surface
markers were performed using the following techniques.10
Murine
Frozen myocardial sections (10 mm) were fixed with 4% paraformalde-
hyde, permeabilized with 0.2% Triton X-100 in TBS, and blocked with
the 5% goat serum. They were incubated with mouse monoclonal anti-
bodies against DSP (Progen, Germany), mouse monoclonal antibody
against plakoglobin (BD Biosciences Pharmingen), rabbit polyclonal
antibody against Cx43 (Invitrogen), or rabbit polyclonal antibody
against the sodium channel (Alomone Labs, Jerusalem, Israel) overnight
at 48C. Sections were washed with TBS and fluorescence-labelled sec-
ondary antibodies (Cy3 goat anti-rabbit and Cy2 goat anti-mouse,
Jackson Immunoresearch, PA, USA) were added for 1 h—they were
examined using confocal microscopy. Analyses were performed with
anonymization of the tissue slides.
Real-time reverse transcriptase polymerase chain reaction
Quantitative real-time reverse transcriptase polymerase chain reaction
(RT–PCR) was performed on mouse hearts using Taqman gene ex-
pression assays (Applied Biosystems, see Supplementary Methods).
All genes were assayed in triplicate with GAPDH as the housekeeping
gene by the 2-DDCt method.
Isolation of murine cardiomyocytes and single cell
electrophysiology
Cardiomyocyte isolation and patch clamping to assess Na channel
current activity were performed using standard techniques (see Sup-
plementary Methods). Peak current inactivation was assessed by
fitting the time-decay with a single exponential using ClampFit10.
Human
Human non-contact mapping studies
Endocardial mapping was performed in 22 patients [DSP mutation
positive (DSP+) n ¼ 10, control (n ¼ 12)]. The control group con-
sisted of patients with supraventricular tachycardia (SVT). They had
normal resting and signal averaged ECGs, a structurally normal heart
on echocardiography and MRI, and no family history of sudden
cardiac death. Informed consent was obtained following local research
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ethics committee approval. The non-contact mapping study and pacing
protocol were performed after SVT ablation in the control patients.
The technique for non-contact mapping in the ventricle has been
described in detail elsewhere.11 The multi-electrode array (Ensite, St
Jude Medical) was deployed via the left femoral vein in the RV
outflow tract (RVOT) (see Supplementary Methods for detailed
protocol).
Human genetic testing
Genomic DNA from ARVC patients and family members was
extracted from whole blood samples using a commercially available
DNA extraction kit (QIAamp DNA Blood mini kit, Qiagen). Index
cases were part of a larger patient cohort comprehensively screened
for mutations in desmoplakin, plakoglobin, plakophilin-2, desmoglein-2,
and desmocollin-2. Primer pairs for DSP exons were designed in flank-
ing intronic sequences and are available on request. Polymerase chain
reaction amplification and direct sequencing on an ABI 3130 Genetic
Analyzer were performed using standard protocols as previously
described.12 –14 A total of 300 unrelated healthy, ethnically matched
Caucasian volunteers served as controls.
Human study protocol
All patients were studied in the post-prandial state and had stopped
anti-dysrhythmic medications for at least five half-lives. After 3 min
of steady-state RV apical pacing at 400 ms, an extrastimulus (S2) was
introduced after a drive train of 10 beats according to a standard
S1–S2 restitution protocol (see Supplementary Methods). A VT stimu-
lation protocol was also performed (Supplementary Methods). The
time from the pacing artefact to electrogram peak negative dV/dt
was used as the local activation time (AT). Activation–recovery inter-
val (ARI) was defined as the interval between activation time (AT) and
repolarization time (RT) and measured as previously described—the
Wyatt method was used to measure ARI durations.15,16 The
maximal slope of the ARI restitution curve (Smax) was calculated
using the least mean squares method.17 The RV was divided into 16
anatomical segments and the restitution slopes studied in the segments
from the RVOT, RV body, and apex.16
Human endocardial regional delay and endocardial local
activation delay
Mean increase of delay was calculated as described above.9 The degree
of delay was measured from four segments in the RVOT, the RV body,
and apex, respectively. Areas of local activation delay during sinus
rhythm were determined using activation gradient quantification as
previously described.16 Where slow conduction occurred on the
map (i.e. greatest local activation delay), the three-dimensional pos-
ition, activation gradient (AG) magnitude, and coefficient of determin-
ation (r2) which is a measure of uniformity of wavefront propagation
along the endocardial surface were calculated.
Human fractionation index
Endocardial electrograms were filtered at 0.1–100 Hz with a signal to
noise ratio set at 1.4 and the number peaks of the differentiated elec-
trogram signal counted as a measure of Fractionation Index—an anala-
gous method to previously published techniques.18,19 Fractionated
electrograms had greater than two deflections.
The human and murine electrophysiological data were anonymized
and analysed blinded to the genetic status using semi-automated signal-
processing techniques with human verification of signal quality and the
electrophysiological measurements.
Human histology and immunostaining
Myocardial biopsies were obtained from three subjects (5, 8, and 9)
and immunostained according to the previously published techniques
as described for the murine tissue above.10
Statistical analysis
Statistical analysis was performed using GraphPad Prism v4 and Sigma-
Stat ver. 3.11, 2004. Full details of the analysis are provided in Supple-
mentary Material. Two-sided P-values less than 0.05 were considered
statistically significant.
Results
Murine
Murine model
We generated mice with cardiac haploinsufficiency of desmoplakin
by intercrossing mice with the cre recombinase under the control
of the aMHC promoter and mice with exon 2 of the desmoplakin
gene flanked by loxP sites. The study mice (aMHC cre+, DSP
flx\+) were compared with littermate controls (C57\Bl back-
ground). As previously reported, we obtained no mice with the
aMHC cre+, flx\flx genotype because of probable embryonic
lethality.20 Genotyping of the DSP (flx\+), cre+, and controls
was confirmed by PCR from genomic DNA (Figure 1A). Quantita-
tive real-time RT–PCR confirmed that there was an approximately
50% reduction in expression compared with control in the aMHC
cre+, DSP flx\+ group (Figure 1E).
Murine electrophysiological parameters and response to
programmed electrical stimulation
The electrophysiological phenotype at 2 months of age was deter-
mined. There were no significant differences in the resting surface
ECG and invasive electrophysiological parameters between the
aMHC cre+, DSP flx\+ mice and controls (Figure 1B, Table 1).
However, a significantly greater proportion of these mice devel-
oped inducible VT [9/11 aMHC cre+, DSP flx\+ vs. 0/10
control, P ¼ 0.0002, (Figure 1C)]. Furthermore, significant differ-
ences in the activation time curve profiles, particularly at shorter
coupling intervals, were identified on model fitting (Figure 1D)
(P, 0.001). However, the mean increase in delay data was not
statistically different (WT 9.48+ 1.35 ms/ms vs. MHC cre+,
DSP flx\+ 9.89+ 0.90 ms/ms, P ¼ 0.8).
Sodium current in isolated myocytes
One explanation for the slowing of conduction and inducibilty of
VT would be changes in Na current density. Thus, Na currents
were compared between control and aMHC cre+, DSP flx\+
mice, by using single-cell patch clamping. No difference in the
maximum Na currents or SCN5A expression from ventricular car-
diomyocytes isolated from control mice or desmoplakin+ litter-
mates were detected (Figure 1E and F ). The I/V relationships of
INa were similar in the two animal groups and the t of inactivation
of INa was not significantly different (Figure 1F).
Echocardiography and histology
Although there was no difference in LV dimensions and function on
echocardiography (LVIs/LVId 0.22/0.34 cm vs. 0.2/0.36 cm, n ¼ 5 in
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Figure 1 (A) Screening of mouse tail DNA by PCR—the floxed DSP allele gives a 410 bp band and the wild-type (WT) allele gives a 320 bp
band. (B) Example of a murine surface ECG recording. (C) Example of single premature extrastimulus (S2) causing polymorphic ventricular
tachycardia. (RA, right atrial intracardiac electrogram; RV, right ventricular intracardiac electrogram; ECG, surface ECG recording; stim, stimu-
lator output). (D) Activation time curves (AT) normalized to baseline AT for mice by genotype (AT, activation time) (n ¼ 10 WT, n ¼ 11
DSP+). (E) Relative mRNA expression by genotype by RT–PCR in 2-month-old desmoplakin (+) myocytes vs. WT (n ¼ 10 WT, n ¼ 11
DSP+). (F ) Electrophysiology of the Na+ current using patch–clamp technique: current traces (left), I/V relationships (top right), and electro-
physiological parameters (bottom right).
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each group) (Figure 2A), there was evidence of slippage of individual
myocardial strands in the RV sections of the aMHC cre+, DSP
flx\+ mice but no change in left ventricular sections (Figure 2B).
Importantly, there was no evidence of replacement of myocytes
with fibro-fatty tissue and interstitial fibrosis in 2-month-old mice
who underwent EP studies (Figure 2B). However, in 6-month-old
mice, focal myocyte loss and fibro-fatty replacement are observed,
showing that DSP aMHC cre+, DSP flx\+ mice do develop histo-
logical abnormalities with time (Figure 2B and C)). A second ex-
planation for the slowed CV would be changes in Cx43.
Immunohistochemistry in 2-month-old mice demonstrated
reductions in Cx43 signal as corroborated by quantitative real-time
RT–PCR (Figure 1E) and less co-localization with b-catenin,
forming cytoplasmic aggregates of Cx43. b-Catenin was used as
a marker of the intercalated disk and its’ signal and localization
remained constant between the genotypes; therefore, there was
less Cx43 at the intercalated disk (Figure 3A). Nav1.5 was found
at the disk, in the endoplasmic reticulum and on the actin filaments
(Figure 3B). It did not show any reduction in signal or change in lo-
calization in the a MHC cre+, DSP flx\+ animals. There was no
change in the localization of plakoglobin in the mice that under-
went electrophysiology studies (Figure 3C). DSP signal at the inter-
calated disk was reduced in aMHC cre+, DSP flx\+ mice
(Figure 3D). However, 6-month-old mice did show reduced levels
of DSP and a small reduction in plakoglobin signal at the interca-
lated disks (Figure 3E and F ).
Human
Patient characteristics
The demographics and clinical features of the DSP study subjects
are shown in Table 2; mean age was 44(+15) years. These patients
had been identified in families with desmoplakin mutations and a
clinical diagnosis of ARVC based upon the most recent Task
Force criteria, with 5/10 having a definite diagnosis, 4/10 border-
line, and possible in 1/10.21– 25 The patients had well preserved
left ventricular function except one subject (no. 5) who had an
ejection fraction of 40%. No other patients had significant RV or
LV wall motion abnormalities meeting ARVC Task Force Criteria.
Seven DSP patients received an ICD, one received post-VF arrest,
and six received secondary prevention due to a history of unex-
plained syncope (3) or documented VT in the context of family
history of sudden cardiac death (2)/impaired left ventricular func-
tion (1). Three patients received appropriate ICD shock therapies
(mean FUp 72 months) (see Supplementary material online, Table
S1 for further details). The 12 control subjects with SVT (no
history of atrial fibrillation, Table 1 shows baseline electrophysio-
logical characteristics) and structurally normal hearts had an
equivalent mean age of 44 (+21) years and sex distribution
(3M:9F).
Isochronal mapping to identify the site of maximal delay
Figure 4 illustrates the isochronal maps recorded during RV apical
pacing at 400 ms obtained from a control and DSP mutation
carrier (DSP+). There is clearly a more prolonged RV depolariza-
tion in the DSP+ patient. However, in the group data, mean endo-
cardial activation time in patients with DSP disease was not
significantly different from controls either in sinus rhythm (41+8
vs. 40+5 ms in controls) or with steady-state RV apical pacing at
400 ms cycle length (42+13 vs. 42+8 ms).
Quantification of regional and local conduction delay
Employing an alternative well-validated method to quantify the
extent of regional conduction delay and inhomogeneity,26,27 no sig-
nificant reductions in activation gradient at the site of slowest con-
duction in sinus rhythm were identified in DSP mutation carriers
[0.4+ 0.1 mm/ms in DSP+ patients vs. 0.47+0.15 mm/ms in
control patients (P ¼ ns)]. The uniformity of wavefront propaga-
tion as measured by r2 was 0.98+0.02 for DSP+ patients vs.
0.94+ 0.04 for controls (P, 0.05).
However, on multiple regression analysis, overall DSP+
patients’ hearts had significantly more prolonged AT restitution
curve profiles vs. controls at CI, 250 ms (P, 0.001) (see Supple-
mentary material online, Figure S1). These delays were also signifi-
cantly different in each of the three RV regions—RVOT, body, and
apex between the DSP mutation carriers and controls (P, 0.001
per region). Furthermore, statistically significant regional
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Table 1 Surface ECG and electrophysiological parameters
Interval WT (ms) (n5 10) SEM (+) Het KO (ms) (n 5 11) SEM (+) Human SVT control (ms) (n5 12) SEM (+)
RR 114 3 110 3.9 760 38
PR 38 0.8 38 1.1 146 27
QTc 23 0.9 24 1.6 374 50
QRS 9 0.1 10 0.3 90 4
SNRT 121 6.5 113 6.2
cSNRT 21 4 16 3.1
AVW 57 3.1 58 3.1 302 35
AV 2:1 45 2.4 48 2.8
AVNERP 46 3.2 45 3.5 250 30
VERP 34 3.2 27 3.2 212 6
VT duration 2229 606
VT CL 37 3.1
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conduction delays occurred in the RVOT measuring 38% greater
than controls (Figure 4B). This corresponds to the delayed activa-
tion time profiles in the DSP+ mice.
Fractionation of electrograms and endocardial
activation–recovery interval restitution curves
Applying the definition of fractionation stated above, DSP+ hearts
had a significantly greater degree of fractionation vs. controls and
was most marked in the RVOT (Figure 5A–C). Figure 5 demon-
strates this regionality of fractionation in subject 8, illustrating
examples of electrogram morphology in RVOT and apical sites
compared with equivalent sites in controls.
The mean ARI of all the segmental restitution curves at 400 ms
baseline cycle length in the DSP+ RV and control RV during RV
apical pacing were compared (Figure 5D–F). Analysis of all the
curves by model fitting and testing for interaction confirmed signifi-
cant differences in the ARI at RVOT, RV body vs. apex in DSP+
patients at both long and short coupling intervals (CI’s) which did
not occur in controls. In control subjects, the ARI curves show a sig-
nificant ARI prolongation only in the RVOT when compared with
the apex over a large range of CI’s (P, 0.001), but the mean RV
body ARI curves were similar to the apex (Figure 5D). However,
in the DSP+ patients, the RV body and RVOT both had significantly
greater ARI prolongation than the apex (P, 0.001).
Not only were there differences between regions in the DSP+
group data, differences in the ARI restitution curves could be iden-
tified between equivalent RV regions in the patient populations. As
seen in Figure 5D, the ARI curves in control subjects show a profile
in which they maximize and then curve downwards with increasing
CI’s. This profile was similar at the RVOT, body, and the apex.
However, in the DSP+ group, the curves at the apex, RV body,
and RVOT were more linear in this range of CI’s. The ARI
values for any given coupling interval were longer in the RV
body and RVOT for DSP+ patients vs. the same regions in con-
trols (P, 0.001) (Figure 5E and F ). This indicates that there is a
large interval dependent dispersion of ARI in the DSP+ patients.
The maximal slopes of ARI restitution curves were compared
between control and DSP+ subjects. The odds of having a
segment with a Smax . 1 was 99% higher (95% CI: 13%; 351%,
P ¼ 0.017) in the DSP+ group.
Immunohistochemistry of human biopsies
One patient had impaired LV function (no. 5) and underwent RV
biopsy. There was no evidence of fibro-fatty replacement, but pla-
koglobin and desmosmal Cx43 expression was downregulated
(Figure 6A). In two other cases without cardiac imaging anomalies,
RV biopsies showed that Nav 1.5 was localized away from the
intercalated disk, marked by b-catenin, aggregating in the cyto-
plasm of the myocytes (subject 8, Figure 6B (i)) or on the actin fila-
ments (subject 9, Figure 6B (ii)). This differs from the absence of Na
channel mislocalization identified in the DSP+ mice.
Discussion
The principle findings in the DSP+ mice include (i) evidence of
slow conduction at short coupling intervals and inducibilty of VT
Figure 2 (A) M-mode echocardiogram of a desmoplakin (+) mouse. (B) Histological features of DSP het KO mice (Masson’s trichrome stain)
illustrating fibrosis in 6-month-old DSP+ stained in blue. (C) Oil red O staining in 8-week and 6-month-old Het KO mice illustrating accumu-
lation of fat droplets with age.
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and (ii) a subtle histological substrate with mislocalization and
reduced intercalated disc expression of Cx43 in the absence of
fibro-fatty changes at 2 months of age but preserved Na channel
activity on patch clamping. Similarly, in human desmoplakin muta-
tion carriers, there was significant conduction delay at short coup-
ling intervals with no evidence of fibro-fatty replacement, but
desmosmal Cx43 expression was also downregulated with some
evidence of Na channel mislocalization. The major novel findings
in this study are that electrophysiological abnormalities occur
prior to major structural changes such as fibrosis in both the
human disease and a murine model. Secondly, this occurs
because of slowed conduction due to a mislocalization and a re-
duction in expression of Cx43.
Murine models of arrhythmogenic right
ventricular cardiomyopathy
We investigated early electrophysiological changes in a cardiac
haploinsufficient desmoplakin murine model. Ventricular tachycar-
dia was readily induced together with conduction delay prior to
the structural changes revealed by echocardiography and conven-
tional histology. This conduction delay was coupled with reduced
intercalated disc Cx43 localization. Na channels were not misloca-
lized away from the sarcolemma as supported by patch clamping.
Thus, haploinsufficiency of desmoplakin is sufficient to result in
Cx43 mislocalization, conduction slowing, and an arrhythmic
phenotype. In a previous study on a similar model, it was con-
cluded that nuclear localization of plakoglobin suppressed Wnt/
beta-catenin signalling and fibro-fatty replacement developed due
to changes in myocyte gene expression.28,29 The electrophysio-
logical phenotype was not examined before overt pathological
changes occurred. In the only published murine model of clinical
DSP mutations, a transgenic mouse expressing the C-terminal mu-
tation R2834H had major structural anomalies. Cx43 and plakoglo-
bin were redistributed to the detergent soluble fraction of the
heart cell lysate, but electrophysiological assessment was not per-
formed.30 In plakoglobin-deficient mice, there were no detectable
structural histological or Cx43 abnormalities. However, prolonged
RV activation time, increased ventricular ectopic burden, and RV
dilatation were associated with increased age and training.31
Figure 3 Representative immunofluorescence images of murine ventricular myocardium. (A) Cx43, (B) Nav1.5, (C) Plakoglobin (PG), (D)
DSP labelling, all 8-week-old mice. (E) Plakoglobin and (F) DSP immunohistochemistry from 6-month-old mice. n¼4 per genotype with con-
sistent staining in each mouse.
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Transgenic mice with cardiac restricted expression of a clinically
identified desmoglein-2 gene mutation (N271S) recapitulated clin-
ical features including spontaneous ventricular arrhythmias and
sudden death, cardiac dysfunction, biventricular dilatation, and ven-
tricular aneurysms. However, such models overexpress mutant
alleles which are not seen in the clinical situation. Again, a detailed
characterization of the cardiac electrophysiology remains to be
undertaken.32 Therefore, the majority of murine ARVC models
demonstrate a profound structural phenotype and the arrhythmic
burden has been studied in this context. Uniquely, we demonstrate
that an electrophysiological substrate exists due to conduction
slowing and Cx43 mislocalization prior to major structural and
histological changes.
Sodium channel effects
In the human biopsy samples, the Na channel appeared to localize
to the intercalated disc in one patient, while in another it was
retained intracellularly and might potentially contribute to a
reduced CV. A potential reason for the difference between the
murine model where no changes in Na channel activity occurred
and man is human mutations may have a different genetic mechan-
ism from simple haploinsufficiency, e.g. missense mutations could
result in gain-of-function or dominant-negative effects. Therefore,
such mechanisms could result in a more severe cellular lesion
which might additionally involve the Na channel.
Human mapping studies in
arrhythmogenic right ventricular
cardiomyopathy
In an analogous manner, previous clinical electrophysiological
mapping studies in ARVC examined patients with advanced
disease where structural abnormalities were evident on conven-
tional imaging. Both Corrado et al.33 and Calkins and co-authors34
have demonstrated fractionation and conduction delay, respective-
ly. However, these studies were conducted mainly in non-
genotyped patients who fulfilled Task Force Criteria with advanced
structural disease, for example in Corrado’s population, 81% had
RV wall motion abnormalities. Furthermore, voltage mapping
alone may miss areas containing less than 40% fibro-fatty endocar-
dial tissue replacement.35 Gadolinium enhanced MRI is even less
sensitive missing 91% of scar with ,20% RV area.36 Our study
of DSP mutation carriers confirms that not only does conduction
delay and electrogram fractionation develop early in this form of
ARVC before detectable cardiac imaging abnormalities, but it can
precede overt histological changes. These conduction delays only
became evident with shorter coupling intervals, demonstrated by
the activation delay curves, particularly in the RVOT. This can be
explained by a number of factors affecting propagation in the RV,
including variable path length at shorter coupling intervals, a
change from longitudinal to transverse conduction, wave front
curvature, differences in gap junction distribution, and channel
kinetics. The increased fractionation could be explained by dissoci-
ation of the myocyte layers as heterogeneity in gap junction distri-
bution and early fibrosis will promote discontinuous myocardial
conduction pathways. A similar pattern was observed in the
cardiac desmoplakin haploinsufficient mice which had delayed
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Electrophysiological abnormalities precede overt structural changes 1949
conduction but only at shorter coupling intervals compared with
controls. Thus, increased stress on myocardial conduction was
required to demonstrate differences in the conduction reserve of
the tissue most probably due to the less overt structural
changes. Only as the disease transitions to more extensive fibro-
fatty replacement then do activation gradients and RV activation
times become more prolonged at long coupling intervals and at
resting heart rates when conduction reserve diminishes further,
consistent with the findings of the Calkins group.34
Our human mapping data also demonstrated additional regional
electrophysiological abnormalities that are difficult to investigate in
the mouse. Significantly prolonged ARI’s were identified in the
RVOT and RV body even at short coupling intervals, a function
of the fact that conduction delay in these regions most probably
prevented engagement of the proximal portion of the ARI restitu-
tion curve in these segments. These apical–basal gradients in ARI
particularly in the RV body would create ideal conditions for con-
duction block and re-entry at both resting and increased heart
rates, therefore increasing the probability of ventricular arrhyth-
mia. Interestingly, despite the more marked conduction delay,
the probability of a DSP+ patient’s RV having an Smax . 1 was
increased, indicating that the substrate was more likely to
promote wave break and VF. This has important implications
since it is well recognized that sudden cardiac death can occur
in patients with minimal histological changes in the sub-clinical
phase of ARVC and thus a more sophisticated clinical phenotyping
approach examining these dynamic conduction–repolarization
changes is required.
Clinical implications
These data may also explain the early phase of the disease when
ventricular tachyarrhythmias and sudden death occur at short
coupling intervals during stress, exercise, or sports activity
(increased adrenergic drive) due to the initial reduction in conduc-
tion reserve and steep Smax. In contrast, during later phases of
ARVC when demonstrable structural changes ensue (fibrosis and
myocyte atrophy), ventricular arrhythmias are more common at
rest as a monomorphic VT. The advanced structural changes
promote greater conduction delay at longer coupling intervals to
prevent engagement of the proximal portion of the ARI restitution
curve reducing the possibility of VT degenerating into VF which
occurs in the early subclinical phase. Therefore, the ventricular
arrhythmias in ARVC may arise from different mechanisms as
the disease progresses with the development of structural
changes over time.
The early manifestations of ARVC are subclinical, escaping de-
tection on conventional imaging and the surface ECG. In this
study of desmoplakin disease, subclinical electrophysiological
effects precede any overt structural changes in a murine
model and in patients. High-density electrophysiological
mapping of the substrate in cases with suspected ARVC may
reveal differences in conduction and repolarization kinetics to
aid identification of cases where close monitoring is indicated
for disease progression.
Study limitations
The human mapping technique evaluates endocardial electrophysi-
ology and thus mid-myocardial and epicardial effects of DSP
disease could not be assessed. This is important since mapping
studies suggest that structural changes manifest epicardially prior
to progressing endocardially. It was not possible to perform high-
density mapping in vivo in the murine model, a technique requiring
further development since this would provide more physiological
data in the innervated murine heart as opposed to current techni-
ques which generally utilize a unloaded, denervated Langendorff
preparation. The qPCR and immunohistochemical results
showing down regulation in Cx43 could not be verified by
western blotting since we were not convinced that the specified
commercial antibody was appropriately detecting the protein.
However western blotting for Cx43 has been shown to be more
sensitive than immunostaining in other models.37
There was only limited human biopsy material available to study
Na channel distribution in the patients. These observations need to
be verified in a larger cohort.
Figure 4 (A) Isochronal map showing RV activation sequence with steady-state pacing from RV apex at 400 ms cycle length (subject 5 vs.
control). PV, pulmonary valve. (B) Mean increase delay according to the region in DSP+ and control groups.
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Conclusion
Abnormalities in desmoplakin expression in a murine model and
human desmoplakin mutation carriers result in significant
changes in conduction and repolarization kinetics prior to struc-
tural changes. The data support the view that ARVC is a desmoso-
somal disease caused by desmosomal protein mutations affecting
myocyte electrical coupling, primarily Cx43 mislocalization, and
promoting structural changes as the disease progresses through
different phases. Cx43 mislocalization is sufficient and central to
the development of an arrhythmic phenotype. The clinical detec-
tion of these early electrophysiological manifestations using high-
density mapping of conduction–repolarization characteristics has
important implications both in the earlier diagnosis of ARVC
before structural changes become evident and improved risk strati-
fication of this challenging condition.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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